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Abstract
Nonalcoholic fatty liver disease (NAFLD) is common in 
the elderly, in whom it carries a more substantial bur-
den of hepatic (nonalcoholic steatohepatitis, cirrhosis 
and hepatocellular carcinoma) and extra-hepatic mani-
festations and complications (cardiovascular disease, 
extrahepatic neoplasms) than in younger age groups. 
Therefore, proper identification and management of 
this condition is a major task for clinical geriatricians 
and geriatric hepatologists. In this paper, the epide-
miology and pathophysiology of this condition are re-
viewed, and a full discussion of the link between NAFLD 
and the aspects that are peculiar to elderly individuals 
is provided; these aspects include frailty, multimorbid-
ity, polypharmacy and dementia. The proper treatment 
strategy will have to consider the peculiarities of geriat-
ric patients, so a multidisciplinary approach is manda-
tory. Non-pharmacological treatment (diet and physical 
exercise) has to be tailored individually considering the 
physical limitations of most elderly people and the need 
for an adequate caloric supply. Similarly, the choice of 
drug treatment must carefully balance the benefits and 
risks in terms of adverse events and pharmacological 
interactions in the common context of both multiple 
health conditions and polypharmacy. In conclusion, 
further epidemiological and pathophysiological insight 
is warranted. More accurate understanding of the mo-
lecular mechanisms of geriatric NAFLD will help in iden-
tifying the most appropriate diagnostic and therapeutic 
approach for individual elderly patients.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Nonalcoholic fatty liver disease (NAFLD) is a 
common disease in the elderly, in whom it follows a 
more severe course due to worse hepatic and extrahe-
patic manifestations. The former include nonalcoholic 
steatohepatitis and hepatocellular carcinoma; the latter 
include cardiovascular and metabolic complications. The 
pathophysiology, diagnosis and principles of treatment 
that are specifically relevant to elderly patients with 
NAFLD are critically revised here. Based on these find-
ings, we conclude that a more accurate understanding 
of the molecular mechanisms of geriatric NAFLD will 
help in identifying the most appropriate diagnostic and 
therapeutic approach in the individual elderly patient.
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BACKGROUND
Increased life expectancy has resulted in a dramatic surge 
of  the median age of  the population. Given that such a 
trend is expected to continue, the increased proportion 
of  elderly and very elderly people in future decades will 
undoubtedly represent a relevant challenge in terms of  
health costs and proper resource allocation[1]. With aging, 
the liver undergoes substantial changes in structure and 
function that are associated with significant impairment 
of  many hepatic metabolic and detoxification activi-
ties[2-10] (Table 1).
Non-alcoholic fatty liver disease (NAFLD), the spec-
trum of  hepatic disorders embracing uncomplicated fatty 
liver (i.e., “pure steatosis”) and nonalcoholic steatohepa-
titis (NASH) is associated with features of  metabolic 
syndrome (MS) and several hepatic and extra-hepatic 
complications[11,12]. Not uncommon in young adults, in 
children and teen-agers[13-15], NAFLD occurs more often 
in males than in females[16] and affects mainly the middle-
aged and the elderly given that that risk factors for its 
development tend to increase in prevalence with advanc-
ing age[3,17,18]. Worryingly, older patients show more severe 
biochemical, hematological and histological changes[3], 
and the female sex is no longer protective with increasing 
age[18].
No specific recommendations are provided by the 
available guidelines regarding the diagnostic conduct to 
be followed in the elderly[19]. Accordingly, a non-invasive 
diagnostic approach[20] appears to be more rational in this 
age group. Finally, physical exercise and dietary restriction 
can be very effective in carefully selected patients and 
should be used as part of  a multidisciplinary approach 
to overcome the physical limitations not uncommon in 
older patients[11].
On these grounds, the present review paper aims to 
systematically and critically analyze bibliographic data 
that are specifically relevant to NAFLD in geriatric clini-
cal practice.
EPIDEMIOLOGY AND NATURAL HISTORY 
OF NAFLD
Epidemiological data on NAFLD may be derived from 
studies conducted either in the general population/large 
cohorts or in selected geriatric cohorts.
Epidemiology of NAFLD from general population and 
large cohort studies: Intersected roles of age and gender
Data from studies conducted in three continents are sum-
marized in Table 2[17,18,21-46]. By analyzing such data, the 
role of  gender and age may be discussed in some detail.
Our group previously reported a prevalence of  male 
individuals with NAFLD in published studies[16], support-
ing a role for endocrine determinants in the development 
of  this condition. Most Asian and European studies 
strongly confirm such a view (Table 2). In males, NAFLD 
tends to increase from younger to middle-aged groups 
of  individuals and the prevalence of  disease begins to 
decline at the age of  50 or 60. This has been defined as 
an “inverted U shaped curve”. Of  interest, a study by 
Nakajima, although conducted in a restricted series of  
liver biopsies, was nevertheless able to demonstrate that 
advancing age was inversely correlated with steatosis[47].
Consistent with a protective role of  estrogens, dur-
ing their fertile period, women tend to be spared from 
NAFLD compared to men. However, although they tend 
to develop the disease approximately 10 years later than 
men, post-menopausal women are no longer spared from 
NAFLD. The prevalence of  NAFLD in women tends to 
decrease after the seventh decade of  life based on both 
epidemiological (Table 2) and clinical studies[48].
While hormonal changes have consistently been 
proposed to account for the varying prevalence rates of  
NAFLD in either gender, the explanation of  decreased 
rates of  NAFLD in the elderly is deemed to reflect either 
selectively decreased survival in those with NAFLD[17,39] 
or decreased fatty changes in advanced NASH[49].
Epidemiology and natural history of NAFLD in the 
geriatric age group
Findings from three studies conducted in selected geriat-
ric cohorts are summarized in Table 3[3,50,51]. Information 
from such studies needs to be interpreted with caution 
because the findings may merely reflect bias introduced 
by restricting the analysis to this relatively unique subset 
of  patients[52]. Accordingly, more extensive, less biased 
cohort clinical studies need to be conducted before draw-
ing any significant conclusions on the prevalence and risk 
factors of  NAFLD in geriatric patients.
Our understanding of  the natural history of  NAFLD 
is based on relatively few studies conducted in the United 
States and northern Europe (reviewed in[12,53,54]). Based on 
such studies, it may be concluded that NAFLD carries a 
risk of  both hepatic and extrahepatic disease.
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Table 1  Anatomical and physiological changes associated with 
aging liver
Increased fibrosis with reduced percentage of fat on liver biopsy[3,4]; 
decreased size mirroring decreased hepatic blood flow[5]
Loss of regenerative capacity, i.e. “replicative senescence” involving
cross talks of growth hormone, glycogen synthase kinase 3β and cyclin
D3 and shortening of telomeric ends of chromosomes[5,6]
Increased inflammatory changes, hence the definition of “inflamm-aging”
which, in its turn, has a detrimental effect on the regenerative response[7]
Defective autophagy[8,9]
Decrease in hepatic free radical scavenging system leads to increased 
oxidative stress resulting mainly from non-enzymatic processes in the
liver[5] and is exacerbated by ethanol drinking[10]
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Table 2  Influences of age and gender on non alcoholic fatty liver disease prevalence: Evidence from population-based and large 
cohort studies from three continents[17,18,21-46]
Asia
   Nomura et al[21], 
   1988
Cross sectional study on 2574 Japanese healthy residents 
(1271 males), age 0-70+ yr , FL in 14%
Prevalence of FL in persons under 19 yr old was only 1.2%, and 
increased with age to a maximum (25.6%) in persons 40-49 yr of 
age and then decreased
   Kojima et al[22], 
   2003
Cross-sectional and prospective study on 39151 Japanese 
first-time examinees, 61% males, 12-yr survey period
The prevalence of FL was uniformly high in males and declined 
in those in the 6th and 7th decades. The prevalence in females 
tended to rise gradually with age and declined in those in their 
7th decade of life
   Shen et al[23], 
   2003
4009 administrative officers non-drinkers, aged 20-81 yr, 64% 
males, FL in 12.9%
At multivariate analysis the prevalence of FL was positively 
correlated to several risk factors, including male gender and age 
> 50 yr
   Fan et al[24], 
   2005
This cross-sectional study with randomized multistage stratified 
cluster sampling included 3175 subjects (1218 men) with a mean 
age of 52 yr. FL was found in 661 (20.82%) subjects
Age-adjusted prevalence of FL was significantly higher in men 
than women, and LRA showed that male gender was closely 
related to FL. The prevalence of FL increased with age in both 
sexes, peaking in women 60-69 yr of age, and in men 40-49 yr 
of age. Interestingly, the prevalence was higher in males than 
females under the age of 50, but was lower in males than females 
among people older than 50 yr 
   Chen et al[25], 
   2006
The cross-sectional community study examined 3245 adults in 
a rural village of Taiwan.The prevalence of NAFLD was 11.5% 
(372/3245)
Male sex was an independent risk factors for NAFLD in the 
general population. Age ≥ or 65 yr was inversely related to 
NAFLD
   Park et al[26], 
   2006
Cross-sectional study was performed with data obtained from 
6648 subjects, all of whom were older than 20 yr of age (3530 men 
and 3118 women). The unadjusted and age-adjusted prevalences 
of NAFLD were 18.7% (23% in men, 13.7% in women) and 16.1% 
(21.6% in men, 11.2% in women), respectively
NAFLD prevalence was higher in men than in women. Age was 
an independent predictor of NAFLD in women only. Menopause 
status was an independent predictor of NAFLD
   Zelber-Sagi et al[27], 
   2006
A cross-sectional study of a subsample of the Israeli national 
health survey (n = 352). Three hundred and twenty-six subjects 
(53.4% male, mean age 50.5 ± 10.3) met the inclusion criteria. The 
prevalence of primary NAFLD was 30% (25%-35% 95%CI)
Male gender was found to be an independent risk factor for 
NAFLD which remained significant even after adjustment for 
obesity and abdominal obesity
   Zhou et al[28], 
   2007
A cross-sectional survey of a random sample of 3543 over 7-yr-
old inhabitants in 6 urban and rural areas in China. Among the 
3543 subjects, 609 (17.2%) were diagnosed having FLD (18.0% 
males, 16.7% females, P > 0.05). Among them, the prevalence 
of confirmed alcoholic liver disease (ALD), suspected ALD and 
nonalcoholic fatty liver disease (NAFLD) were 0.4%, 1.8%, and 
15.0%, respectively. The prevalence rate (23.0%) was significantly 
higher in urban areas than (12.9%) in rural areas
The prevalence rate was significantly higher in men than 
in women under the age of 50 yr. However, the opposite 
phenomenon was found over the age of 50 yr
Multivariate and logistic regression analysis indicated that male 
gender was among the independent risk factors for FLD
   Eguchi et al[34], 
   2012
A cross-sectional study was conducted among 8352 subjects 
who received health checkups from 2009 to 2010 in three health 
centers in Japan
The overall prevalence of NAFLD was 29.7%
The prevalence of NAFLD is higher in males than that in females 
at all ages, it is “inverted U-Shaped” in males (peaking at 40-49 
yr); it gradually increases in all age groups in women but 
declines in those ladies in their seventies
   Al-hamoudi et al[35], 
   2012
Prospective study among 1312 patients referred for 
ultrasonography in Saudi Arabia
The prevalence of NAFLD was 16.6% (218/1312)
In a multivariate analysis, younger age and being male were 
significant predictors of high ALT levels
   Wang et al[18], 
   2013
Chinese case-control study based on all 4226 adults above 60 yr 
of age from a previously cohort investigated compared to 3145 
randomly selected younger controls (< 60 yr) from the same 
cohort. NAFDL was higher in the elderly (26.7%) than in the 
non-elderly (22.8%) and similar in the elderly between men and 
women (26.6% vs 27.0%, P > 0.05)
The prevalence of FLD is higher in the elderly, and is broadly 
related to the same metabolic risk factors as in the non-elderly. 
However, female-sex is no longer protective with increasing age, 
and the prevalence of steatohepatitis with advanced fibrosis is 
estimated to be considerably higher in the elderly FLD patients 
than in the younger FLD controls
   Foster et al[36], 
   2013
3056 participants of the Multi Ethnic Study of Atherosclerosis 
were included in this study. NAFLD was defined as LS ratio < 1, 
the prevalence of NAFLD was and 11 % in African Americans
Younger age was among the independent correlates of NAFLD 
in this population
   Xu et al[37], 
   2013
Cross-sectional study on 6905 nonobese (BMI < 25). Risk factors 
for the development of NAFLD were assessed in a subsequent 
prospective study in NAFLD-free individuals at baseline, 494 
of whom had developed NAFLD during the 5-yr follow-up. 
Prevalence of NAFLD was 7.27%
Older age and male gender are associated with both the 
prevalence and the incidence of novel NAFLD cases in a non 
obese Chinese population
   Yan et al[38], 
   2013
Random sampling of 3762 adults Chinese residents. 
Ultrasonography revealed fatty liver in 1486 residents with a 
prevalence of 39.5%
At univariate analysis, NAFLD cases were statistically younger 
and more often males
Europe
   Lonardo et al[39], 
   2006
Hospital cohort study of 449 individuals undergoing both liver 
and carotid US evaluation for clinical indications
U-shaped curve with NAFLD peak prevalence in the 30-39 and 
40-49 age groups. The phenomenon may either reflect a decrease 
of risk factor for NAFLD, (e.g., obesity) or selectively increased 
mortality among those with FL. At logistic regression analysis 
FL is more common in younger male individuals
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treatments, surveillance for HCC is deemed to improve 
the survival rates of  elderly patients[68].
In the elderly, decreased cytochrome P450 activity 
can affect drug metabolism, increasing the susceptibility 
to drug-induced liver injury. Immune responses against 
pathogens or neoplastic cells are reduced in the elderly, 
although these individuals may be predisposed to autoim-
munity through impairment of  dendritic cell maturation 
and reduction of  regulatory T cells. These changes in 
immune functions could alter the pathogenesis of  viral 
hepatitis and autoimmune liver diseases, as well as the de-
velopment of  HCC[69].
Cardiovascular disease, metabolic complications, 
extrahepatic cancer
As is now clear from consistent evidence in the litera-
ture, NAFLD stands not only as a primary disease of  the 
liver but rather as a systemic condition with an inherent 
increased risk for CV disease (CVD). Evidence for a 
link between NAFLD and CVD, notably including ath-
erosclerosis, which occurs independent of  components 
of  MS, has extensively been reviewed by our group and 
others[12,54,70-75]. Such a view is specifically confirmed in 
elderly people.
By evaluating 810 males and 1273 elderly women in 
Japan, Akahoshi et al[76] demonstrated that NAFLD was 
associated with coronary risk factors independent of  
obesity in either gender.
Evidence for those NAFLD patients who are T2D-
free at baseline to develop the disease during the follow-
up period have been extensively reviewed elsewhere[12,54]. 
Cryptogenic cirrhosis and hepatocellular carcinoma
Data suggest that in middle-aged individuals (especially 
in the 45-54 year-old age group), NAFLD is a strong 
independent risk factor for cardiovascular (CV) mor-
tality[55]. NASH-cirrhosis is expected to occur in older 
ladies with multiple metabolic derangements and moder-
ately raised liver enzymes because of  the following four 
reasons: (1) the male sex is typically prone to premature 
coronary deaths; (2) NAFLD occurs in women later 
than in men (Table 2); (3) female gender and older age 
are significantly associated with severe fibrosis[30]; and 
(4) younger ages are associated with more elevated liver 
enzymes[35]. Such a prediction is confirmed by Ludwig 
et al[56] and by more recent evidence. Caldwell et al[57,58], 
by comparing different series of  cirrhosis due to vary-
ing etiologies, concluded by inference that “cryptogenic 
cirrhosis” featuring a prevalence of  female gender, as-
sociated metabolic conditions and slightly raised liver 
enzymes is nothing but NASH-cirrhosis.
Bugianesi et al[59] group went further in identifying the 
risk of  hepatocellular carcinoma (HCC) as a part of  the 
NAFLD disease spectrum, confirming early hypotheses 
published as early as in 1990[60].
Risk factors for HCC in NAFLD include advanced 
age, type 2 diabetes (T2D) and cirrhosis[61-63]. Of  concern, 
however, is that HCC may also develop against the back-
ground of  non-cirrhotic NAFLD[64,65] accounting for the 
finding that these patients are missed by surveillance pro-
grams and are diagnosed later than those associated with 
viral etiology[66,67]. This is of  importance given that, by ex-
panding the percentage of  cancers amenable to effective 
   Bedogni et al[40], 
   2007
A follow-up study on 144 subjects without and 336 with fatty 
liver followed for a median 8.5 yr time
Male sex is a predictor of incidence of fatty liver; male sex and 
age are predictors of death in those with fatty liver
   Caballeria et al[41], 
   2010
multicentre, cross-sectional, populational study recruiting 766 
Individuals between 15 and 85 yr of age randomly selected from 
25 primary healthcare centres in Spain
On multivariate analysis, male sex, age and other factors were 
associated with NAFLD
   Koehler et al[17], 
   2012
2811 participants in the population-based Rotterdam Study. 
Mean age of participants was 76.4 yr (range 65.3-98.7 yr)
NAFLD is common in the elderly. However, the prevalence of 
NAFLD decreased with advancing age suggesting a positive 
selection of the elderly without NAFLD
   Soresi et al[42], 
   2013 
Study on the prevalence of NAFLD in metabolic syndrome Men and women with steatosis were younger than those without 
steatosis. At multivariate analyses, was associated with higher 
ALT
United States of America
   Browning et al[43], 
   2004
An observational study on 2287 subjects from a multiethnic, 
population-based sample (of white, Black, and Hispanic)
In whites, but not in Hispanics or blacks, the frequency of 
hepatic steatosis was approximately 2-fold higher in men than 
in women related to ethanol intake, not to differences in the 
frequency of obesity or insulin resistance
   Younossi et al[44], 
   2012
A retrospective study on 11613 participants included in 
the National Health and Nutrition Examination Survey Ⅲ 
(NHANES Ⅲ); 2185 had NAFLD; and, of these, 307 had NASH
NAFLD was independently associated with younger age and 
female sex; and NASH was independently associated with 
having a younger age in those United States lean individuals 
with NAFLD
   Bambha et al[45], 
   2012
628 adults enrolled either in the observational Database or the 
PIVENS trial between 2004 and 2008 and thus submitted to liver 
biopsy
Advancing age and female gender were among the independent 
predictors of advanced fibrosis at LRA
   North et al[46], 
   2012
A total of 1242 (1064 EA, 178 AA) and 1477 (1150 EA, 327 AA) 
men and women, respectively, underwent CT examination from 
which LA and abdominal adipose volume were measured
Mean LA varied significantly by sex, [(men) 57.76 ± 10.03 HU 
and (women) 60.03 ± 10.91 HU, P = 0.0002], but not by race. 
Higher LA was associated with older age
   Foster et al[36], 
   2013
3056 participants of the Multi Ethnic Study of Atherosclerosis 
were included in this study. NAFLD was defined as LS ratio < 1
Younger age was among the independent correlates of NAFLD 
in this population
AA: African Americans; ALD: Alcoholic liver disease; FL: Fatty liver; FLD: Fatty liver disease; NAFLD: Non alcoholic fatty liver disease; NASH: Non 
alcoholic steatohepatitis.
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Table 3  Selected cohort studies of geriatric patients[3,50,51]
Kagansky et al[50], 2004 In this prospective study, 91 octogenarians who were 
admitted to the rehabilitation departments of a geriatric 
hospital were compared to 46 NAFLD young patients
NAFLD is a common and benign finding in the elderly population, in 
whom it is not associated with the metabolic syndrome
Frith et al[3], 2009 In this retrospective, cohort study set in a tertiary liver 
clinic in United Kingdom. Three hundred and fifty 
one consecutive biopsy-proven NAFLD patients were 
divided into an older (≥ 60), a middle-aged (≥ 50 to < 
60) and a younger (< 50) group
NAFLD affects mainly the middle-aged and the elderly. Older patients 
show more risk factors and more severe laboratori alterations and his-
tological changes, with cirrhotics having a significantly more advanced 
age than those with milder disease
Noureddin et al[51], 2013 A cross-sectional analysis of adult participants who 
were prospectively enrolled in the NASH Clinical 
Research Network studies. Participants were included 
based on availability of the centrally reviewed liver 
histology data within 1 year of enrollment, resulting in 
61 elderly (age ≥ 65 yr) and 735 nonelderly (18-64 yr) 
participants
The main outcomes were the presence of NASH and advanced fibrosis. 
Compared to nonelderly patients with NAFLD, elderly patients had 
a higher prevalence of NASH (56% vs 72%, P = 0.02), and advanced 
fibrosis (25% vs 44%, P = 0.002). Compared to nonelderly patients with 
NASH, elderly patients with NASH had higher rates of advanced 
fibrosis (35% vs 52%, P = 0.03), as well as other features of severe liver 
disease including the presence of ballooning degeneration, acidophil 
bodies, megamitochondria, and Mallory-Denk bodies (P ≤ 0.05 for each)
Clearly, in the elderly, the combination of  T2D with 
NAFLD is likely to manifest a high-risk interaction[62].
Of  particular concern is that NAFLD was associated 
with osteoporotic fractures in middle-aged and elderly 
men in a recent Chinese study[77].
Finally, a line of  research has highlighted NASH (but 
not simple steatosis) as an independent risk factor for 
(particularly right-sided) colonic adenomas and advanced 
neoplasms[78]. Given the strong age-dependency of  the 
disease, findings from this study suggest that colorectal 
cancer screening is strongly indicated in elderly individu-
als with NASH.
In conclusion, NAFLD is neither an uncommon nor 
benign disease in the aged individual.
Elderly people have a high risk for strongly age-depen-
dent hepatic and extra-hepatic complications.
Awareness of  NAFLD epidemiology and natural his-
tory allows prompt recognition of  the disease and the 
management of  complications.
Figure 1A summarizes the epidemiology of  NAFLD 
with respect to age (adapted from References[39,75]).
PATHOPHYSIOLOGY OF AGE-
ASSOCIATED METABOLIC ALTERATIONS 
Liver
An age-specific pattern of  liver disease cannot be de-
fined[79,80]; nonetheless, a number of  pathophysiological 
changes have been described with aging, which can ulti-
mately affect hepatic lipid metabolism.
The reduced liver function, which occurs with aging, 
has been causally associated with a decline in hepatic 
blood flow and liver volume[80]. Specific alterations in the 
metabolism of  drugs with a high hepatic extraction rate 
have been described[81]. However, the metabolic impact 
of  such changes remains unclear. The possible role of  
the alterations in drug disposition on the progression of  
liver disease has been commented above[69].
Age-related alterations in hepatic cholesterol homeo-
stasis are poorly defined. Epidemiological evidence sup-
ports increased serum cholesterol values that tend to pla-
teau in very old individuals[82] and an increased prevalence 
of  gallstone disease[83] with aging. Again, the underlying 
mechanisms are incompletely defined; a limited number 
of  reports on in vivo studies in humans have described a 
reduction in low density lipoprotein turnover[84] and an 
increase in biliary cholesterol output, possibly related to a 
decrease in cholesterol degradation to bile acid[85,86]. Data 
from humans also suggest that a reduction of  whole 
body, and presumably hepatic, cholesterol synthesis oc-
curs with aging[87].
The pathogenesis of  NAFLD undoubtedly involves 
IR[88-91]. However, the role of  IR as a determinant of  age-
related liver disease has been recently questioned on the 
grounds that it may represent a compensatory rather 
than a causal mechanism[92]. Age-related decreases in hor-
mones such as insulin-like growth factor-1 and dehydro-
epiandrosterone contribute to NAFLD development via 
increased IR[93-97].
The role of  glucocorticoids in the balance between 
liver injury and protection is controversial[98]. Hypercor-
tisolism may associate with NAFLD, even if  its preva-
lence in this condition is lower than expected[99]; the anti-
inflammatory effects of  endogenous corticosteroids have 
been evoked in this regard.
The molecular mechanisms leading to hepatic steato-
genesis may theoretically involve increased fat intake (di-
etary uptake and lipogenesis) or decreased fat output (be-
ta-oxidation, lipoprotein secretion)[88,100,101]. The reduced 
beta-oxidation was related to reduced hepatic expression 
of  the nuclear receptors of  the peroxysome proliferator-
activated receptors family (PPARs), whereas the expres-
sion of  liver X receptors (LXRs) was enhanced[102,103]; the 
role of  other nuclear receptors of  the hepatocyte nuclear 
factor (HNF) family cannot be ruled out as well[96,102].
Interestingly, an inverse correlation between NAFLD 
and serum levels of  adipocyte-fatty acid binding protein, 
an intracellular lipid transporter, has been reported in the 
elderly[104].
Human NAFLD in the elderly is frequently more 
NAFLD: Non alcoholic fatty liver disease; NASH: Non alcoholic steatohepatitis.
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severe and therefore carries a worse prognosis than in 
younger age groups. This finding has also been substan-
tiated in a murine model of  steatohepatitis[105]. Aging-
related alterations of  the pro-inflammatory vs anti-
inflammatory balance (described as the “inflamm-aging” 
theory) may represent the biological background of  these 
findings[106].
The pivotal role of  inflammation in the pathogenesis 
Figure 1  Geriatric nonalcoholic fatty liver disease at a glance (modified from Refs[39,75]). A: Epidemiology; B: Pathogenesis; C: Clinical manifestations. Schematic 
representation of chief epidemiological, pathogenic and clinical features of nonalcoholic fatty liver disease (NAFLD) observed in geriatric age based on data critically 
reviewed in the text. From an epidemiological point of view, NAFLD tends to peak in middle life and its occurrence is reduced in the extreme decades. Pathogenically, 
altered body fat distribution and changes in gut microbiota predispose to those metabolic changes which tend to be even more closely associated with NAFLD in the 
elderly than in the young. The biochemical and molecular mechanisms underlying the development of fatty liver may involve insulin resistance and inherent hormonal 
changes, as well as mediators of inflammation and possibly vitamin D and a number nuclear receptors. Regarding the latter, only indirect evidence can be inferred 
from the literature (see text for details). Clinically, NAFLD tends to be associated with the typical geriatric syndromes, such as dementia, sarcopenia, autonomic 
dysfunction, aortic valve sclerosis and autonomic changes predisposing to fatigue, falls and arrhythmia. HNF4: Hepatocyte nuclear factor 4 alpha; IGF-1: Insulin-like 
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of  liver steatosis has been emphasized in the literature; 
the link between insulin resistance and inflammation 
and the possible role of  JNKs in the progression of  
this condition has been clearly defined, along with the 
involvement of  endoplasmic reticulum stress and of  the 
unfolded protein response[71].
In addition, hormonal changes involving the GH/
IGF axis have been related to inflammation in NAFLD. 
In this context, the adipokine pattern plays an important 
role; in particular, circulating levels and tissue expres-
sion of  adiponectin seem to be inversely correlated with 
NAFLD and its progression[107]; a condition of  low-
grade chronic inflammation, where interleukins, in par-
ticular IL-6, play a relevant role, is also present[107]. These 
findings together underscore the complex relationship 
between insulin resistance and inflammation. Increased 
spleen volume has also been correlated with this condi-
tion and with the alterations in the hormonal and inflam-
matory pattern[108].
Finally, the role of  the apoptosis-antiapoptosis bal-
ance has to be considered; serum concentrations of  
Bcl-2, a well-known anti-apoptotic marker, were found to 
be decreased in subjects with NAFLD and NASH[109-111]. 
Serum levels of  Bcl-2 also tended to decrease with in-
creasing age[111], even if  the data in very elderly individu-
als are missing.
Altered distribution of  inflammatory cytokines in the 
different body compartments may further contribute to 
worsening NAFLD course in the elderly[112].
Adipose tissue
Aging is typically associated with profound alterations 
in the amount and distribution of  body fat depots with 
a shift occurring from subcutaneous to visceral localiza-
tion. Such a shift, in turn, is frequently associated with 
chronic conditions linked to increased CVR[113,114] such as 
IR (see above) and other stigmata of  MS[113].
The relationship between IR and epicardial fat con-
tent, a marker of  coronary risk, has been highlighted[115]; 
evidence in humans, although limited, seems to suggest 
that in the elderly, epicardial fat accumulation and liver 
steatosis may be associated[116]. Animal models have 
confirmed that the amount of  adipocytes in fat depots 
increases with aging[117].
Together with the well-known deleterious effects of  
visceral fat accumulation and IR, subcutaneous fat loss, 
and the age-related reduced capacity of  subcutaneous fat 
cells to store lipids may also lead to metabolic complica-
tions via lipotoxic effects[118].
Furthermore, the role of  preadipocytes, fat cell pro-
genitors, in fat distribution and function has been high-
lighted in animals[114] and humans[119]. The decline in pre-
adipocyte proliferation and differentiation described with 
aging may account for an imbalance between lipogenesis 
and lipolysis, ultimately leading to an increased exposure 
to free fatty acids and potential lipotoxicity[120,121]. Among 
the different compounds, saturated fatty acids appear to 
be particularly hepato-toxic[114,122]. Such toxic potential 
translates into stress responses, oxidative stress and in-
creased expression of  proinflammatory cytokines[123].
The constellation of  the alterations in fat cell bio-
chemistry, proliferative capacity and response to inflam-
mation and immune response accompany the process of  
fat cell senescence[118].
Indeed, fine tuning of  the cross-talk between adipo-
genic and anti-adipogenic pathways[120] and together with 
previously mentioned age-related hormonal derange-
ments (GH and IGF-1) and activation of  proinflammato-
ry cytokines cascade may play a specific role in NAFLD 
development in the elderly.
The expression of  nuclear receptors and transcrip-
tional modulators in adipose tissue is fundamental in 
such regulation; the role of  PPARγ and other coactiva-
tors such as CCAAT/enhancer-binding protein α and β 
has been clarified[124-127]. A role for liver X receptors can-
not be ruled out as well, considering its role in adipogen-
esis[128], even if  no definite evidence with respect to aging 
is presently available.
Closely related the above mentioned findings, it is im-
portant to recall the possible therapeutic implications of  
reducing abdominal fat, and not only BMI, in improving 
survival in the elderly, as recently reported[129].
MICROBIOTA IN THE ELDERLY
The human gut microbiome is a complex “superorgan-
ism” that is mostly confined to the colon, which contains 
at least 1014 microorganisms, equal to 1.5 kg of  microbes 
of  5000 species with a predominance of  anaerobic bac-
teria)[130-132]. The collective genome of  gut microbiota, 
termed the metagenome, is composed of  almost 5 mil-
lion genes[133]. Microbiota is considered an “organ within 
an organ”, with its own functions: it modulates the ex-
pression of  genes involved in mucosal barrier develop-
ment, maturation and maintenance of  the GI sensory and 
motor functions and the mucosal immune system[134,135]. 
It also has a critical role in supporting normal digestion, 
affects energy extraction from the diet and produces es-
sential nutrients such as vitamins (e.g., vitamin K, vitamin 
B12 and folic acid) and amino acids, which humans are 
unable to produce themselves[136,137]. In addition, the 
intestinal microbiota participates in the defense against 
pathogens. Compositional changes have been linked with 
inflammatory bowel disease, irritable bowel syndrome 
and metabolic disorders, such as T2D and obesity[138-140].
Microbiota and aging
During adulthood, the composition of  the intestinal mi-
crobiota at the species level is relatively stable. This rela-
tive stability, however, decreases in old age[141,142].
Aging produces modifications in the homeostasis of  
GI microbiota with changes in the prevalence of  differ-
ent bacteria[143]. There is a general agreement regarding 
large inter-individual variability in older subjects, with a 
certain country specificity, possibly related to differences 
in lifestyle and dietary habits[144].
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A decrease in Firmicutes has been reported in the Ital-
ian population over 60 years and centenarians, which is in 
contrast with other European populations. The decrease 
of  both Clostridium cluster XIV and Faecalibacterium praus-
nitzii group members was also correlated with frailty, hos-
pitalization, and antibiotic and non-steroidal anti-inflam-
matory treatment. An age-related increase in Bacteroidetes 
was found in elderly subjects from Northern Europe but 
not in Italian elderly and centenarians[142,145].
Recent studies observed higher levels of  health-promot-
ing bifidobacteria in the elderly in contrast with the com-
mon assumption of  their decreased levels with age[145-147]. 
Certainly, there is an age-related increase in facultative 
anaerobes (like streptococci, staphylococci, enterococci, 
and enterobacteria), and pro-inflammatory pathobionts 
are present in the healthy gut microbiota at low concentra-
tions[142,148,149].
A decrease in immunomodulatory species belonging 
to the Clostridium clusters Ⅳ and ⅩⅣ associated with in-
creased pro-inflammatory pathobionts seems to promote 
inflammatory disorders, and elderly subjects generally 
have reduced immune function, particularly a deteriora-
tion in cell-mediated responses, that affect gut microbiota 
composition[150].
During aging, the impairment of  the gut-associated 
lymphoid tissue and the reduced efficiency of  the innate 
immune defenses are responsible for uncontrolled mi-
crobial growth on the enterocyte surface. Indeed, aging is 
also accompanied by a chronic, low grade overall inflam-
matory status responsible for the development of  patho-
bionts that can support inflammation with compromised 
host longevity[151]. Finally, decreased cellular immune 
functions can lead to an increased emphasis on antibody-
associated responses in the elderly, the subsequent excess 
of  antibodies reflects an increased autoimmunity to self-
antigens, predisposing the person to the development of  
autoimmune diseases[152-154].
In addition to immunosenescence and inflamm-aging, 
lifestyle and dietary habits are other major factors that are 
responsible for age-related changes in microbiota. Diet 
impacts on the selection of  microbial species are able to 
optimize energy extraction from dietary substrates[148,155,156].
Age-related changes in taste and smell sensations, 
tooth loss and chewing difficulties strongly influence diet 
with a reduced intake of  fiber, non-starch carbohydrates 
and proteins, producing modifications in the composition 
of  the bowel ecosystem through a reduction in microbial 
fermentation. In contrast, reduced acid secretion in the 
stomach can lead to bacterial overgrowth and subsequent 
nutrient and vitamin malabsorption[157-160].
An unbalanced diet with inadequate intake of  vitamin 
D and B12, calcium and protein can affect both the com-
position and activity of  intestinal microbiota[161-164]. The 
common decreased sensation of  thirst adversely affects 
bowel motility and bodily water balance[165].
Lifestyle differences, notably including dietary habits, 
may further affect the geographic-dependent modulation 
of  age on microbiota[148].
The poor quality of  the diet associated with dimin-
ished physical activity in the elderly is also responsible for 
reduced intestinal motility, which will result in bacterial 
overgrowth and enhanced metabolic activity, which are 
difficult to control in an immunosenescent host[148,155,166]. 
Age-related neurodegeneration in the enteric nervous 
system may further contribute to impaired bowel peristal-
sis[166,167].
Increased incidence of  disease will be conducive to 
increased drug consumption by elderly individuals, and 
this will eventually alter the composition of  intestinal mi-
crobiota. Most drugs cause hyposalivation responsible for 
changes in oral microbiota, candidiasis and dysphagia[168]. 
Proton pump inhibitors, by lowering gastric pH, may lead 
to malabsorption of  nutrients and microbial overgrowth 
with associated risk of  Clostridium difficile (C. difficile) diar-
rhea[169]. Similarly, broad-spectrum antibiotics may lead 
to overgrowth of  pathogenic bacteria such as C. difficile; 
however, non-absorbable antibiotics (e.g., rifaximin) play 
a therapeutic role in restoring intestinal microbiota imbal-
ance in several intestinal disorders. The frequent use of  
nonsteroidal anti-inflammatory drugs is associated with 
mucosal gastric and duodenal damage with alteration in 
the local ecosystem[170]. Finally, the use of  opioids may 
lead to reduced intestinal motility and subsequent bacte-
rial overgrowth[171].
Figure 1B illustrates in a schematic way some aspects 
of  the pathophysiology and pathogenesis of  the relation-
ship between aging and NAFLD.
NAFLD AND THE GERIATRIC 
SYNDROMES: SARCOPENIA, FRAILTY, 
DEMENTIA
The relationship between NAFLD and the typical clinical 
syndromes associated with aging is ill-defined. Some of  
the clinical manifestations associated with NAFLD are 
schematically summarized in Figure 1C.
Sarcopenia and frailty
Sarcopenia is characterized by reduced muscle mass and 
strength[172] and replacement of  muscle with adipose 
and fibrous tissue; sarcopenia represents one of  the 
hallmarks of  frailty, according to its commonly adopted 
definition[173].
The documentation of  an association between fat 
accumulation in the two tissues (liver and muscle) is rela-
tively recent: morphological imaging has shown that fat 
content in the paravertebral muscles is correlated with ag-
ing and steatosis based on CT analysis and suggested that 
a reduction in muscle fat can be associated with an im-
provement of  steatosis[174]. A very recent paper by Hong 
et al[175], on behalf  of  the Korean Sarcopenic Obesity 
Study, has provided substantial evidence of  a correlation 
between fat liver content, expressed as the liver attenua-
tion index at CT, and the skeletal muscle mass index de-
termined by DXA.
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Sarcopenia and NAFLD may share a number of  
pathophysiological mechanisms. First, IR has been con-
sistently associated with both conditions. The relation-
ship between IR (and the inherent presence of  the MS) 
and NAFLD has long been recognized[89-91] and critically 
reviewed[92], as discussed above. The relationship between 
IR and sarcopenia has been outlined more recently: me-
diated by mitochondrial dysfunction, IR seems to be a 
key mediator of  the loss of  muscle mass[176]. Closing the 
circle, intramuscular steatosis, which occurs with aging, is 
associated with IR[177].
A strong relationship links body mass and insulin 
sensitivity in younger subjects[178] and presumably in the 
elderly as well.
Interestingly, Hong et al[175] reported an inverse corre-
lation between IR and muscle mass, and a direct correla-
tion between IR and liver fat accumulation, supporting a 
common pathophysiological substrate of  the two condi-
tions mediated by IR itself. Consistent with this view, the 
MS that is associated with IR has also been associated 
with NAFLD and sarcopenia[179].
Inflammation represents another factor that potential-
ly links sarcopenia to NAFLD. The association between 
NASH and inflammation[13], or “inflamm-aging[106], is well 
known, as discussed above. A number of  epidemiologi-
cal studies have also shown an association between low 
grade inflammation and sarcopenia[180]. Several circulating 
markers of  inflammation, such as TNF-α and interleu-
kins (IL-6 in particular) as well as CRP, have clearly been 
associated with sarcopenia and hepatic steatosis[175,180]. In-
flammation is obviously related to IR, as discussed above, 
and the possible pathophysiological role of  increased cy-
tokine release from adipose tissue in the elderly[89] needs 
to be emphasized.
Finally, a possible role for vitamin D needs to be em-
phasized. Several lines of  evidence have shown that low 
vitamin D levels are associated with sarcopenia, on the one 
hand[181], and with NAFLD on the other[182]. A possible 
common pathophysiological substrate involving shared mo-
lecular pathways[183] is highly plausible. However, no such 
association was observed in Asian populations[175,184].
Dementia
Cognitive decline is another typical feature of  pathologi-
cal aging, which might be associated with liver disease in 
general. Apart from the well-known association between 
end-stage liver failure and encephalopathy, the presence 
of  more subtle mechanisms linking “milder” liver dis-
ease and some forms of  cognitive decline deserves full 
consideration. For instance, primary biliary cirrhosis and 
hepatitis C have been correlated with some forms of  
neuropsychological impairment even in earlier stages of  
the disease[185,186]. NAFLD has recently been postulated to 
be an additional risk factor for dementia[187] and is associ-
ated with carotid atherosclerosis[39,188] which, in turn, can 
heavily impair cognitive function.
Apart from the obvious effects of  cerebrovascular 
disease, hormonal alterations associated with NAFLD 
and possibly linked to IR may play a role; among these, 
the reduction of  IGF-1 levels, as previously discussed[93]. 
Interestingly, IR was found to be associated with visual 
and cognitive performance deficits that are strictly linked 
with frailty and dementia[189].
A possible link with vitamin B12, folate and homocys-
teine levels also needs to be considered. An association 
between low levels of  vitamin B12 and NAFLD is de-
scribed in the literature[190]. A similar relationship between 
dementia and vitamin B12 deficiency is well known[191]; 
an increased plasma concentration of  homocysteine, 
often caused by cobalamine and folate deficiency, is also 
a strong, independent risk factor for the development 
of  dementia and Alzheimer’s disease[192]. Although there 
are no studies that compare the three conditions, the 
presence of  a common pathway linking dementia with 
NAFLD (vitamin B12 and folate deficiency, higher levels 
of  homocysteine) seems plausible.
AUTONOMIC AND CARDIOVASCULAR 
CHANGES IN NAFLD
Autonomic changes can be measured to assess heart rate 
variability (HRV), that defines non-invasively and with a 
high repeatability cardiac autonomic function[193,194]. Fre-
quent symptoms of  cardiac autonomic dysregulation are 
fatigue, orthostatic hypotension and vasovagal syncope. 
A strong association links NAFLD, autonomic chang-
es, and MS. Liu et al[195] showed an association between 
NAFLD and the natural logarithm of  standard deviation 
of  NN (lnSDNN) after adjustment for the main CVR 
factors. Moreover, these authors showed a relationship 
between MS and an index of  sympathetic activity at the 
symbolic dynamics analysis of  HRV[196], indicating activa-
tion of  sympathetic tone in NAFLD patients. 
Studies have reported a high prevalence of  autonomic 
dysfunction in patients with chronic liver disease[197]. 
Most NAFLD patients do not present with symptoms 
directly attributable to their liver disease. It is increasingly 
recognized, however, that those with NAFLD report a 
wide ranging spectrum of  non-specific symptoms, such 
as fatigue and daytime sleepiness, which may be the pre-
senting complaint and may dramatically impact quality 
of  life[198]. Fatigue is a significant issue in NAFLD, the 
severity of  which does not mirror the severity of  hepatic 
histological changes and dysfunction but is associated 
with daytime sleepiness and autonomic dysfunction[198]. 
Dysfunction of  the autonomic nervous system leads to 
symptoms such as postural dizziness and syncope and is 
also associated with a number of  clinical consequences in 
hepatic diseases such as cognitive dysfunction, falls and 
fall-related injuries. Falls are also considered a direct con-
sequence of  autonomic nervous system dysfunction[198]. 
Newton demonstrated that a history of  falls is common 
in NAFLD (43%). The proportion of  recurrent fallers 
was significantly higher in a NAFLD cohort compared to 
controls, with injuries, emergency medical attention, frac-
ture rates and hospital admission all being significantly 
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more common in the NAFLD group, independent of  
the presence of  T2D or the severity of  liver disease[198].
Fatigue is a significant symptom in NAFLD that 
impacts quality of  life and is unrelated to liver disease 
severity. Newton et al[199] demonstrated a relationship be-
tween fatigue and altered autonomic response, higher or-
thostatic symptoms, and a higher prevalence of  positive 
response to head-up tilt test.
Recognition of  systemic symptoms in NAFLD has 
important implications for patients because many are 
potentially modifiable with targeted interventions. Several 
authors demonstrated that an 8-wk resistance exercise 
program improves sympathovagal balance, expressed as 
LF/HF ratio measured at rest, and HR and blood pres-
sure response to submaximal exercise[200].
The spectrum of  CVD associated with NAFLD ex-
tends beyond the commonly recognized premature ath-
erosclerosis. In particular, arrhythmia and non-rheumatic 
aortic valve sclerosis (a common finding in geriatric prac-
tice) have been recently included among CV complica-
tions of  NAFLD[75].
The prevalence of  atrial fibrillation (AF) increases 
from approximately 1% in individuals less than 55 years 
of  age to approximately 10%-12% in those older than 80 
years of  age[201]. Along with older age, many pathologic 
conditions such as obesity, hypertension, coronary heart 
disease, heart failure and heart valve disease are the stron-
gest risk factors for new-onset AF, which is a disease 
associated with high rates of  hospitalization and death. 
Not unexpectedly, given that NAFLD is associated with 
multiple abnormalities in cardiac structure and function 
and shares multiple cardiometabolic risk factors with AF, 
an association between NAFLD and an increased risk of  
incident AF in patients older than 60 years and T2D, in-
dependent of  other CVR factors[202] has recently been re-
ported. It may be postulated that NAFLD is a marker of  
ectopic fat accumulation in other tissues, including both 
the myocardium and pericardium. Rijzewijk et al[203] and 
Ng et al[204] showed that the intramyocardial fat content, as 
detected by proton magnetic resonance spectroscopy, was 
greater in patients with T2D than in nondiabetic controls 
and was associated with LV diastolic dysfunction. More-
over, it is possible that NAFLD is not only associated 
with the risk of  AF as the consequence of  the shared 
risk factors but that NAFLD per se might partly contrib-
ute to the development and persistence of  AF, through 
the systemic release of  pathogenic mediators from the 
steatotic and inflamed liver, including C-reactive protein, 
interleukin-6, tumor necrosis factor-alpha, plasminogen 
activator inhibitor-1 and other inflammatory cytokines; 
these pathogenic mediators are remarkably higher in pa-
tients with NAFLD than in those without, as commented 
above, and may play a role in the development and per-
sistence of  AF, possibly by inducing structural and/or 
electrical remodeling of  the atria[205,206].
Finally, plasma homocysteine levels, a well-known risk 
factor for CV and cerebrovascular disease, are higher in 
patients with NAFLD[207]. No direct evidence for a corre-
lation that links aging, NAFLD, homocysteine levels and 
CV disease is available; however, an association of  these 
factors, as mentioned above for dementia, seems likely.
PRINCIPLES OF NAFLD MANAGEMENT 
IN THE ELDERLY
Lifestyle changes
Given that geriatric NAFLD is not a benign disease, el-
derly patients have a high necessity of  treatment. Of  con-
cern, lifestyle changes including diet and exercise, which 
are universally recommended as a first-line approach[19] 
and which may particularly improve autonomic dysfunc-
tion[200], are unlikely to be accepted by elderly individuals. 
Therefore, the results appear to be largely unpredict-
able[208] in this specific age-group, particularly regarding 
increased physical activity[209]. 
The findings that decreased choline intake is associ-
ated with increased fibrosis in postmenopausal NAFLD 
women[210] and that fish consumption decreases HCC 
risk[211,212] fully support the recommendation for a bal-
anced diet in the elderly NAFLD patient[213].
Drug treatment
Drug treatment is an alternative/adjunctive approach to 
lifestyle changes. Such a choice might, in principle, ap-
pear to be more effective than lifestyle changes. However, 
to date, no drug has been specifically approved for use 
in NAFLD[208]. Moreover, current guidelines provide no 
specific therapeutic recommendations for those older 
than 65 years[19]. Finally, aging and NAFLD per se may 
expose these patients to a higher risk of  polypharmacy 
and adverse drug reactions including drug-induced liver 
injury[214-216].
In the elderly, special attention should be paid to the 
early identification of  cirrhosis and to the diagnosis and 
treatment of  its complications. No significant differences 
in diagnostic investigations or treatment options are ob-
served between the elderly and the young[217] except that 
liver transplantation is more rarely performed in the for-
mer age group. Fibrosis progression is best detected and 
monitored through non-invasive techniques[218]. However, 
after careful consideration of  the cost/benefit balance 
of  this procedure, liver biopsy might be considered in 
selected elderly patients[51].
Next we discuss the principles of  treatment of  the 
main metabolic risk factors associated with NAFLD in 
the elderly.
Dyslipidemia
Dyslipidemia in NAFLD individuals generally requires 
aggressive management[219]. Statins, the main cholesterol-
lowering class of  drugs, are the most effective and 
widely used for the primary and secondary prevention 
of  CVD[220]. Statins are remarkably safe in NAFLD pa-
tients[70,221,222]. The available small sample of  mostly non-
randomized studies have shown limited evidence of  
hepatic histological benefit in NAFLD[19,223]. Recently, 
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two studies have shown that statins reduce CV events in 
patients with increased transaminases presumably due 
to NAFLD. Moreover, one of  them reported that the 
CVD benefit was greater than in patients with normal 
liver tests[224]. Given that CVD is the main cause of  death 
in NAFLD patients[75], statins play a key role in NAFLD 
management[225]. Finally, statins may also exert a poten-
tially beneficial role both on portal hypertension and 
HCC chemoprevention[226-230].
Therapeutic options in the elderly must carefully bal-
ance the potential CV benefits vs the possible side effects 
and risk of  drug interactions. No universal guidelines may 
be proposed, and treatment decisions need to be tailored 
considering the specific features of  the individual patient, 
such as biological age, comorbidities and functional organ 
impairment[231].
Diabetes 
Metformin is the first-line drug for the treatment of  T2D. 
Despite beneficial effects on IR, it exerts only a small 
effect on serum aminotransferases and fails to improve 
liver histology in NAFLD[232]. Accordingly, metformin 
should not be used in non-diabetic NAFLD patients[19] 
although it has important beneficial effects on NAFLD 
complications/comorbidities: metformin moderately re-
duces the risk of  HCC[233-235] and significantly decreases 
arterial stiffness, a predictor of  cardiovascular mortali-
ty[236]. A particular concern in the elderly is represented by 
the frequent impairment of  liver function, requiring the 
need for individualized dosage and warning that metfor-
min is contra-indicated in the presence of  overt kidney 
failure.
Glitazones (i.e., pioglitazone) are recommended by 
current guidelines for the treatment of  subjects with 
NASH. Large randomized controlled trials reported 
a beneficial effect of  pioglitazone on systemic IR and 
liver histology, although the advantage was limited for 
fibrosis[237-239]. However, the beneficial effects on liver 
histology disappeared after treatment discontinuation[240]. 
Moreover, pioglitazone - due to increased subcutaneous 
fat depots - is associated with weight gain; the increased 
risk of  congestive heart failure and bone fractures and a 
slightly increased risk of  bladder cancer limit its clinical 
appeal[19], especially in the elderly.
Finally, preliminary evidence for potentially favorable 
action has been described in an experimental model with 
pharmacological agents inducing a small increase in mito-
chondrial uncoupling, leading to an improvement of  T2D 
and IR associated with decreased hepatic steatosis[241].
Hypertension 
Angiotensin receptor blockers are widely used antihy-
pertensive agents with a well-characterized safety profile. 
Chronic liver damage up-regulates the local tissue renin-
angiotensin system, which contributes to the recruitment 
of  inflammatory cells and the development of  fibrosis[70]. 
Some animal and small sample human studies have sug-
gested that angiotensin receptor blockers improve serum 
liver enzyme levels and histological features of  NAFLD; 
however, further larger clinical trials are needed to cor-
roborate these findings[75].
Recently, telmisartan has prevented hepatocarcino-
genesis via inhibited hepatic angiogenesis in a rat NASH 
model[242].
When considering treatment with blood pressure-
lowering agents, attention needs to be paid to the risk of  
orthostatic hypotension (see above).
Obesity
The association between NAFLD and obesity in the 
elderly may be less relevant due to a physiologic weight 
loss occurring with aging[39]. Lifestyle modification 
through hypocaloric diet and increased physical activity is 
the mainstay of  the treatment of  obesity. A 5% to 10% 
weight loss is recommended to improve steatosis and 
NASH[19]. Consolidated habits and common physical lim-
itations hamper lifestyle changes in the elderly. No spe-
cific drugs are approved for weight-loss, and indications 
to perform bariatric surgery are restricted by reduced life 
expectancy and comorbidities of  elderly patients.
Vitamin E
Vitamin E (800 IU/d) has been shown able to improve 
NASH histological features (except for fibrosis)[19]. How-
ever, no long-term follow-up data are available, and this 
vitamin is not recommended in those with diabetes[243]. 
Of  major concern, high-dose Vitamin E supplementa-
tion has been linked to increased all-cause mortality[244].
Vitamin D 
Vitamin D deficiency is common in the elderly[245]. An 
increasing body of  evidence suggests that low vitamin D 
status is associated with NAFLD and its histological se-
verity as well as to T2D, MS and CV events[75]. Random-
ized clinical trials are needed to determine whether vita-
min D supplementation improves NAFLD and reduces 
the incidence of  cardiovascular outcomes.
Prebiotics and probiotics
Dietary prebiotic consumption, which modulates gut 
microbiota[246], although associated with subjective satiety, 
reduced postprandial glucose and insulin concentrations, 
exhibits inconsistent results regarding total energy intake, 
body weight, gut peptides, insulin sensitivity, serum lipids, 
inflammatory markers and immune function[247]. More-
over, despite encouraging results in animals[248-250], the 
effect of  probiotics on metabolic parameters have pro-
vided conflicting results in humans. Transplantation of  
intestinal microbiota from lean donors improves insulin 
sensitivity in subjects with MS[251]. The wide use of  this 
interesting approach, however, is likely to be limited by 
the potential risk of  transmitting the recipient (unknown) 
pathogens. Further studies are needed to identify strate-
gies to target gut microbiota composition as an innova-
tive NAFLD treatment in the elderly.
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CONCLUSION
Aging is a major social and economic challenge that will 
steadily increase in the coming decades. NAFLD is ex-
pected to play an important role in age-related liver dis-
ease in the setting of  the secular worldwide trend towards 
an increment of  metabolic diseases, notably including 
those associated with reduced insulin sensitivity such as 
obesity and T2D.
Of  concern, NAFLD in the elderly is expected to carry 
a substantial burden of  NASH, cirrhosis and HCC, which 
along with the worrying extra-hepatic manifestations and 
correlates of  disease, makes proper identification and man-
agement of  this condition a major task for clinical geriatri-
cians and geriatric hepatologists. Careful consideration of  
the aspects that are peculiar to elderly subjects, including 
the typical geriatric syndromes (frailty, multimorbidity, 
polypharmacy, and dementia), is also required.
Proper treatment strategies will have to consider the 
peculiarities of  the geriatric population and will require a 
multidisciplinary approach. Non-pharmacological treat-
ment (diet and physical exercise) has to be individually 
tailored considering the physical limitations of  most el-
derly people and the need for an adequate caloric supply. 
Similarly, the choice for drug treatment must carefully 
balance the benefits and costs in terms of  adverse events 
and pharmacological interactions, in the common context 
of  both multiple comorbidities and polypharmacy.
Further epidemiological and pathophysiological insight 
is warranted. More accurate understanding of  the molecu-
lar mechanisms of  geriatric NAFLD will help in identifying 
the most appropriate diagnostic and therapeutic approach 
in individual elderly patients. 
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